Bruker Corporation to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Bruker (BRKR) has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco. The company will be represented by Frank Laukien (Chairman, President & CEO), Mark Munch (Executive Vice President & President of Bruker Nano Group), and Gerald Herman (Executive Vice President & CFO).
The presentation is scheduled for Monday, January 13th, 2025, at 3:45 PM Pacific Standard Time. Investors can access a live audio webcast through the company's investor relations website at ir.bruker.com. A replay will be available in the 'Events & Presentations' section for 30 days following the event.
Bruker (BRKR) ha annunciato la sua partecipazione al 43° Annual J.P. Morgan Healthcare Conference a San Francisco. L'azienda sarà rappresentata da Frank Laukien (Presidente, Amministratore Delegato & CEO), Mark Munch (Vice Presidente Esecutivo & Presidente di Bruker Nano Group) e Gerald Herman (Vice Presidente Esecutivo & CFO).
La presentazione è programmata per lunedì 13 gennaio 2025, alle 15:45 ora del Pacifico. Gli investitori possono accedere a una diretta audio sul sito delle relazioni con gli investitori dell'azienda su ir.bruker.com. Una registrazione sarà disponibile nella sezione 'Eventi & Presentazioni' per 30 giorni dopo l'evento.
Bruker (BRKR) ha anunciado su participación en la 43ª Conferencia Anual de J.P. Morgan sobre Atención Médica en San Francisco. La compañía estará representada por Frank Laukien (Presidente, CEO & Director General), Mark Munch (Vicepresidente Ejecutivo y Presidente del Grupo Bruker Nano) y Gerald Herman (Vicepresidente Ejecutivo y CFO).
La presentación está programada para el lunes 13 de enero de 2025, a las 3:45 PM hora estándar del Pacífico. Los inversores pueden acceder a una transmisión en audio en vivo a través del sitio web de relaciones con inversores de la compañía en ir.bruker.com. Una grabación estará disponible en la sección 'Eventos y Presentaciones' durante 30 días después del evento.
Bruker (BRKR)는 샌프란시스코에서 열리는 제43회 JP 모건 헬스케어 컨퍼런스에 참가한다고 발표했습니다. 회사는 Frank Laukien (회장, 사장 & CEO), Mark Munch (전무 부사장 & Bruker Nano Group 대통령), Gerald Herman (전무 부사장 & CFO)으로 구성된 대표단을 보낼 예정입니다.
발표는 2025년 1월 13일 월요일, 태평양 표준시 기준 오후 3시 45분에 예정되어 있습니다. 투자자는 회사의 투자자 관계 웹사이트인 ir.bruker.com을 통해 생중계 오디오 웹캐스트에 접속할 수 있습니다. 이벤트 후 30일 동안 '이벤트 및 발표' 섹션에서 재생 가능할 것입니다.
Bruker (BRKR) a annoncé sa participation à la 43e Conférence Annuelle J.P. Morgan sur les Soins de Santé à San Francisco. L'entreprise sera représentée par Frank Laukien (Président, PDG et CEO), Mark Munch (Vice-président Exécutif et Président de Bruker Nano Group) et Gerald Herman (Vice-président Exécutif et CFO).
La présentation est prévue pour le lundi 13 janvier 2025 à 15h45, heure standard du Pacifique. Les investisseurs peuvent accéder à un webinaire audio en direct via le site web des relations avec les investisseurs de la société à ir.bruker.com. Un enregistrement sera disponible dans la section 'Événements & Présentations' pendant 30 jours après l'événement.
Bruker (BRKR) hat seine Teilnahme an der 43. jährlichen J.P. Morgan Healthcare-Konferenz in San Francisco bekannt gegeben. Das Unternehmen wird vertreten durch Frank Laukien (Vorsitzender, Präsident & CEO), Mark Munch (Executive Vice President & Präsident von Bruker Nano Group) und Gerald Herman (Executive Vice President & CFO).
Die Präsentation ist für Montag, den 13. Januar 2025, um 15:45 Uhr Pacific Standard Time angesetzt. Investoren können über die Investor-Relations-Website des Unternehmens unter ir.bruker.com auf eine Live-Audio-Webcast zugreifen. Eine Aufzeichnung wird für 30 Tage nach der Veranstaltung im Bereich 'Events & Präsentationen' verfügbar sein.
- None.
- None.
A live audio webcast of the presentation will be available on the Investor Relations section of the Company's website at https://ir.bruker.com. A replay of the presentation will be posted in the “Events & Presentations” section of the Bruker Corporation Investor Relations website after the event and will be available for 30 days following the presentation.
About Bruker Corporation – Leader of the Post-Genomic Era (Nasdaq: BRKR)
Bruker is enabling scientists and engineers to make breakthrough post-genomic discoveries and develop new applications that improve the quality of human life. Bruker’s high performance scientific instruments and high value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular, and microscopic levels. In close cooperation with our customers, Bruker is enabling innovation, improved productivity, and customer success in post-genomic life science molecular and cell biology research, in applied and biopharma applications, in microscopy and nanoanalysis, as well as in industrial and cleantech research, and next-gen semiconductor metrology in support of AI. Bruker offers differentiated, high value life science and diagnostics systems and solutions in preclinical imaging, clinical phenomics research, proteomics and multiomics, spatial and single-cell biology, functional structural and condensate biology, as well as in clinical microbiology and molecular diagnostics. For more information, please visit www.bruker.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250107351795/en/
Joe Kostka
Director, Investor Relations
Bruker Corporation
T: +1 (978) 313-5800
E: Investor.Relations@bruker.com
Source: Bruker Corporation
FAQ
When is Bruker (BRKR) presenting at the 2025 J.P. Morgan Healthcare Conference?
How can investors watch Bruker's (BRKR) J.P. Morgan Healthcare Conference presentation?
How long will the replay of BRKR's 2025 J.P. Morgan Healthcare presentation be available?
Which executives will represent Bruker (BRKR) at the 2025 J.P. Morgan Healthcare Conference?
